# HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

> **NCT04564872** · PHASE3 · COMPLETED · sponsor: **Sichuan Haisco Pharmaceutical Group Co., Ltd** · enrollment: 465 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** HSK7653 10 mg Q2W
- **DRUG:** HSK7653 25 mg Q2W
- **DRUG:** Linagliptin 5 mg QD

## Key facts

- **NCT ID:** NCT04564872
- **Lead sponsor:** Sichuan Haisco Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-13
- **Primary completion:** 2022-01-21
- **Final completion:** 2022-08-29
- **Target enrollment:** 465 (ACTUAL)
- **Last updated:** 2022-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04564872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04564872, "HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04564872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*